StockData

Amylyx Pharmaceuticals vs Bicycle Therapeutics

AMLX and BCYC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMLX and BCYC compare

Amylyx Pharmaceuticals is the larger company, worth 14 times as much as Bicycle Therapeutics ($3.4B against $236M).

Bicycle Therapeutics scores higher on the StockData Score (11 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMLXBCYC
Size and price
Market cap$3.4B$236M
Share price$30.29$3.37
Change, 1 year146%−48.6%
Change, 5 years182%−94.2%
Beta (5Y)1.151.37
Employees136288
StockData Score
Total score711 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score12 (better)
Health score6 (better)4
Dividend score00
Valuation
P/S–2.8×
P/B4.5×0.5× (better)
FCF yield–−74.9%
Fair value–$16.02
Margin of safety–79.0%
Growth
Revenue growth (TTM)–195%
Revenue growth, 5Y average–47.5%
Profitability
Operating margin–−189%
Net margin–−170%
FCF margin–−212%
Return on equity−30.1%−25.2% (better)
Return on invested capital–−4543%
Financial health
Debt / equity0.000.00
Interest coverage–−815.6×
Current ratio26.81 (better)12.09
Altman Z-score60.09 (better)0.04
Piotroski F-score4 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%53.4%
Held by insiders7.8%21.3%
Insider net buying, 12 months−$17.2M−$523K (better)
Short interest, % of float12.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.